Online citations, reference lists, and bibliographies.
Referencing for people who value simplicity, privacy, and speed.
Get Citationsy
← Back to Search

Biomaterial-associated Thrombosis: Roles Of Coagulation Factors, Complement, Platelets And Leukocytes.

M. Gorbet, M. Sefton
Published 2004 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Our failure to produce truly non-thrombogenic materials may reflect a failure to fully understand the mechanisms of biomaterial-associated thrombosis. The community has focused on minimizing coagulation or minimizing platelet adhesion and activation. We have infrequently considered the interactions between the two although we are generally familiar with these interactions. However, we have rarely considered in the context of biomaterial-associated thrombosis the other major players in blood: complement and leukocytes. Biomaterials are known agonists of complement and leukocyte activation, but this is frequently studied only in the context of inflammation. For us, thrombosis is a special case of inflammation. Here we summarize current perspectives on all four of these components in thrombosis and with biomaterials and cardiovascular devices. We also briefly highlight a few features of biomaterial-associated thrombosis that are not often considered in the biomaterials literature: The importance of tissue factor and the extrinsic coagulation system. Complement activation as a prelude to platelet activation and its role in thrombosis. The role of leukocytes in thrombin formation. The differing time scales of these contributions.
This paper references
10.1016/0735-1097(93)90715-D
Histology after stenting of human saphenous vein bypass grafts: observations from surgically excised grafts 3 to 320 days after stent implantation.
H. V. van Beusekom (1993)
10.1056/NEJMRA043430
Inflammation, atherosclerosis, and coronary artery disease.
G. Hansson (2005)
10.1016/S0022-5223(19)35477-7
Endotoxins in cardiopulmonary bypass.
L. Nilsson (1990)
A model for the tissue factor pathway to thrombin. I. An empirical study.
J. H. Lawson (1994)
10.1073/PNAS.74.12.5260
Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation.
B. Osterud (1977)
10.1016/1054-8807(93)90059-B
Chapter 18 Complement activation by biomaterials
R. Hakim (1993)
10.1002/JOR.1100170603
Measurement and removal of adherent endotoxin from titanium particles and implant surfaces
A. Ragab (1999)
10.1038/KI.1990.317
Induction of IL-1 during hemodialysis: transmembrane passage of intact endotoxins (LPS).
M. Laude-Sharp (1990)
10.1161/01.CIR.100.5.553
Role of C3 cleavage in monocyte activation during extracorporeal circulation.
C. Rinder (1999)
10.1055/S-0038-1651046
Adhesion of polymorphonuclear leukocytes to protein-coated and platelet adherent surfaces.
D. Morley (1989)
10.1177/088532828900400202
Complement Activation During Hemodialysis
A. Agostoni (1989)
10.1159/000232186
Inhibition of the interaction between the complement component Clq and immune complexes.
R. Allan (1979)
10.1002/(SICI)1097-4636(199902)44:2<130::AID-JBM2>3.0.CO;2-9
Human plasma fibrinogen adsorption and platelet adhesion to polystyrene.
W. Tsai (1999)
10.1002/(SICI)1097-4636(19990905)46:3<434::AID-JBM17>3.0.CO;2-L
Decontaminating particles exposed to bacterial endotoxin (LPS).
V. Hitchins (1999)
10.1055/S-0038-1657509
Contact activation: a revision.
A. Schmaier (1997)
10.1182/BLOOD.V77.12.2641.BLOODJOURNAL77122641
Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles.
G. Tans (1991)
10.1016/0735-1097(91)90943-4
Prospects for the use of antagonists to the platelet glycoprotein IIb/IIIa receptor to prevent post-angioplasty restenosis and thrombosis.
S. Ellis (1991)
10.1016/S0735-1097(97)00070-3
Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty.
C. Serrano (1997)
10.1182/BLOOD.V82.11.3350.BLOODJOURNAL82113350
Mechanisms of Thrombin Generation During Surgery and Cardiopulmonary Bypass
Boisclair (1993)
Interactions of neutrophils and coagulation proteins.
S. Gillis (1997)
10.1016/0003-4975(93)90264-I
Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass.
A. Gillinov (1993)
10.1016/S0022-5223(94)70287-X
Circulating cytokines in patients undergoing normothermic cardiopulmonary bypass.
B. Fréring (1994)
10.1136/heart.86.6.e18
Acute profound thrombocytopenia following angioplasty: the dilemma in the management and a review of the literature
S. N. Makoni (2001)
10.1097/00002480-199407000-00060
Tumor necrosis factor monoclonal antibody prevents alterations in leukocyte populations during cardiopulmonary bypass.
R. Vertrees (1994)
10.1016/S0142-9612(99)00101-5
Dissociation between complement activation, integrin expression and neutropenia during hemodialysis.
Y. Rousseau (1999)
10.1002/(SICI)1097-4636(19980915)41:4<657::AID-JBM18>3.0.CO;2-B
Hemocompatibility of treated polystyrene substrates: contact activation, platelet adhesion, and procoagulant activity of adherent platelets.
J. Grunkemeier (1998)
10.1111/J.1523-1755.1998.00836.X
Rapid activation of the complement system by cuprophane depends on complement component C4.
K. Lhotta (1998)
10.1172/JCI111865
Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition.
S. Hanson (1985)
10.1055/S-0038-1650224
Nafamostat mesilate, a broad spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulation.
S. Sundaram (1996)
Platelet Immunobiology: Molecular and Clinical Aspects
T. Kunicki (1989)
10.1067/MLC.2001.114066
Polymorphonuclear leukocytes in coagulating whole blood recognize hydrophilic and hydrophobic titanium surfaces by different adhesion receptors and show different patterns of receptor expression.
C. Eriksson (2001)
10.1161/01.ATV.12.10.1111
Initiation and regulation of tissue factor-dependent blood coagulation.
S. Rapaport (1992)
10.1182/BLOOD.V88.9.3432.BLOODJOURNAL8893432
Blood clotting in minimally altered whole blood.
M. Rand (1996)
10.1093/NDT/9.4.389
Enhancement of reactive oxygen species production and cell surface markers expression due to haemodialysis.
J. Cristol (1994)
10.1002/JBM.820281008
Adherent platelet morphology on adsorbed fibrinogen: effects of protein incubation time and albumin addition.
J. Sheppard (1994)
10.1182/BLOOD.V89.6.2131
Neutrophil adhesion to fibrinogen and fibrin under flow conditions is diminished by activation and L-selectin shedding.
P. Kuijper (1997)
10.1097/00003246-198807000-00028
Disorders of Hemostasis and Thrombosis
R. Bick (1985)
10.1016/0735-1097(96)00183-0
Coronary stent occlusion: thrombus horribilis.
J. A. Bittl (1996)
10.1002/JBM.A.10155
Material-induced tissue factor expression but not CD11b upregulation depends on the presence of platelets.
M. Gorbet (2003)
10.1016/S0022-5223(96)70275-1
Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial.
D. Muehrcke (1996)
10.1016/0092-8674(91)90279-8
Leukocyte-endothelial cell recognition: Three (or more) steps to specificity and diversity
E. Butcher (1991)
10.1016/0735-1097(95)00563-3
Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty.
F. Neumann (1996)
10.1115/1.429634
Vortex shedding as a mechanism for free emboli formation in mechanical heart valves.
D. Bluestein (2000)
10.1136/JCP.39.3.352
Bacterial Endotoxins. Structure, Biomedical Significance, and Detection with the Limulus Amebocyte Lysate Test
I. Poxton (1985)
Role of complement activation in cell adhesion to polymer blood contact surfaces.
Herzlinger Ga (1980)
Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions.
Marcus Aj (1994)
10.1056/nejm199404073301402
Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.
Epic Investigators (1994)
10.1111/J.1525-1594.1984.TB04291.X
Complement activation during hemodialysis: clinical observations, proposed mechanisms, and theoretical implications.
D. Chenoweth (1984)
10.1055/S-0038-1650305
Pentamidine is a specific, non-peptide, GPIIb/IIIa antagonist.
D. Cox (1996)
10.1002/(SICI)1097-4636(199711)37:2<176::AID-JBM5>3.0.CO;2-O
Flow cytometric analysis of material-induced platelet activation in a canine model: elevated microparticle levels and reduced platelet life span.
C. Gemmell (1997)
10.1084/JEM.179.6.1847
Simultaneous expression of tissue factor and tissue factor pathway inhibitor by human monocytes. A potential mechanism for localized control of blood coagulation
M. Mcgee (1994)
10.1002/JBM.820251012
Platelet consumption by NHLBI reference materials and SILASTIC [corrected].
W. Ip (1991)
10.1182/BLOOD.V87.11.4651.BLOODJOURNAL87114651
Platelet-derived microparticles associate with fibrin during thrombosis.
P. Siljander (1996)
10.1055/S-0038-1647499
Endotoxin-induced platelet activation in human whole blood in vitro.
G. Csako (1988)
10.1055/S-0038-1649806
Protein tyrosine phosphorylation in human platelets during shear stress-induced platelet aggregation (SIPA) is regulated by glycoprotein (GP) Ib/IX as well as GP IIb/IIIa and requires intact cytoskeleton and endogenous ADP.
A. Oda (1995)
10.1016/B978-012448510-5/50164-3
Commentary on and reprint of EPIC (Evaluation of 7E3 for the Prevention of Ischemic Complications) Investigators, The, Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty, in New England Journal of Medicine (1994) 330:956–961
M. Lichtman (2000)
10.1055/S-0037-1614643
Glycoprotein IIb/IIIa receptor antagonist tirofiban inhibits thrombin generation during cardiopulmonary bypass in baboons.
A. Rao (1999)
10.1016/1043-6618(92)90214-V
Platelet-dependent modulation of neutrophil function.
G. Bazzoni (1992)
10.1016/0142-9612(88)90066-X
Activation of the complement system at the interface between blood and artificial surfaces.
M. Kazatchkine (1988)
10.1067/MLC.2001.114677
Leukocyte activation and leukocyte procoagulant activities after blood contact with polystyrene and polyethylene glycol-immobilized polystyrene beads.
M. Gorbet (2001)
10.1038/KI.1991.324
Adherence of neutrophils to hemodialysis membranes: role of complement receptors.
A. Cheung (1991)
10.1016/0142-9612(92)90086-4
Adsorption of coagulation proteins from whole blood on to polymer materials: relation to platelet activation.
J. Elam (1992)
10.1055/S-0038-1651568
The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene.
F. Rubens (1993)
Flow cytometric analysis of leukocytes eluted from haemodialysers.
A. Castiglione (1991)
10.1016/S0140-6736(77)90727-9
INTRAVENOUS LIGNOCAINE IN PREVENTION OF DEEP VENOUS THROMBOSIS AFTER ELECTIVE HIP SURGERY
E. Cooke (1977)
10.1097/00005344-199600001-00005
Amplification of the inflammatory response: adhesion molecules associated with platelet/white cell responses.
C. Rinder (1996)
10.1182/BLOOD.V81.3.734.BLOODJOURNAL813734
Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation
J. Morrissey (1993)
10.1016/S0003-4975(96)00942-3
Extracorporeal circulation, hemocompatibility, and biomaterials.
G. Janvier (1996)
10.1016/S0006-3495(95)80087-1
Selectin- and integrin-mediated T-lymphocyte rolling and arrest on TNF-alpha-activated endothelium: augmentation by erythrocytes.
R. Melder (1995)
10.1182/BLOOD.V89.1.166.166_166_175
Platelet and fibrin deposition at the damaged vessel wall: cooperative substrates for neutrophil adhesion under flow conditions.
P. Kuijper (1997)
Distinct adhesive properties of granulocytes and monocytes to endothelial cells under static and stirred conditions.
T. Kuijpers (1990)
10.1055/S-0038-1642679
Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions.
A. Marcus (1994)
10.1055/S-0037-1614982
Monocyte procoagulant activity induced by adherence to an artificial surface is reduced by end-point immobilized heparin-coating of the surface.
R. Barstad (1998)
10.1016/S0142-9612(99)00012-5
Characterization of transient platelet contacts on a polyvinyl alcohol hydrogel by video microscopy.
M. Godo (1999)
10.1016/S0003-4975(98)00727-9
Effects of cardiopulmonary bypass on leukocyte and endothelial adhesion molecules.
G. Asimakopoulos (1998)
10.1002/JBM.A.30354
Complement inhibition reduces material-induced leukocyte activation with PEG modified polystyrene beads (Tentagel) but not polystyrene beads.
M. Gorbet (2005)
10.1016/S0003-4975(00)01093-6
Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration.
J. Defraigne (2000)
10.1016/S0022-5223(99)70302-8
Heparin-coated cardiopulmonary bypass equipment. II. Mechanisms for reduced complement activation in vivo.
V. Videm (1999)
10.3109/14017439609107259
Time Course of β2-Integrin CD11b/CD18 (Mac-1, αMβ2) Upregulation on Neutrophils and Monocytes after Coronary Artery Bypass Grafting: CD11b upregulation after CABG surgery
A. Takala (1996)
10.1002/(SICI)1097-4636(19981215)42:4<611::AID-JBM18>3.0.CO;2-D
Assessment of material-induced procoagulant activity by a modified Russell viper venom coagulation time test.
C. Gemmell (1998)
Platelet activation in whole blood by artificial surfaces: identification of platelet-derived microparticles and activated platelet binding to leukocytes as material-induced activation events.
C. Gemmell (1995)
10.1016/0003-4975(92)91018-5
Time for new concepts about measurement of complement activation by cardiopulmonary bypass?
V. Videm (1992)
10.1111/j.1365-2141.1989.tb07712.x
Platelet‐dependent induction and amplification of polymorphonuclear leucocyte lysosomal enzyme release
A. Maschio (1989)
10.1002/JBM.820270302
The blood compatibility catastrophe.
B. Ratner (1993)
10.1084/JEM.178.6.2147
Fibrin(ogen) mediates acute inflammatory responses to biomaterials
L. Tang (1993)
10.1016/0142-9612(92)90057-U
Adsorption of baboon fibrinogen and the adhesion of platelets to a thin film polymer deposited by radio-frequency glow discharge of allylamine.
J. Chinn (1992)
Is prosthetic valve thrombogenicity related to design or material
Edmunds Lh (1996)
10.1182/blood.v83.9.2498.bloodjournal8392498
Role of P-selectin and leukocyte activation in polymorphonuclear cell adhesion to surface adherent activated platelets under physiologic shear conditions (an injury vessel wall model).
E. Yeo (1994)
10.1016/S0171-2985(98)80030-2
Platelet receptors for the complement component C1q: implications for hemostasis and thrombosis.
E. I. Peerschke (1998)
10.1056/NEJM197403072901002
Platelet survival in patients with substitute heart valves.
H. Weily (1974)
10.1093/OXFORDJOURNALS.EURHEARTJ.A015200
Reduction of monocyte-platelet interaction and monocyte activation in patients receiving antiplatelet therapy after coronary stent implantation.
A. May (1997)
10.1111/J.1525-1594.1989.TB02842.X
Beta-2-microglobulin and main granulocyte components in hemodialysis patients.
M. Haag‐Weber (1989)
10.1161/01.CIR.96.10.3534
Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant.
R. Nieuwland (1997)
Inflammatory responses to implanted polymeric biomaterials: role of surface-adsorbed immunoglobulin G.
L. Tang (1993)
10.1016/S0008-6363(96)88553-1
Neutrophil activation in paediatric extracorporeal circuits: effect of circulation and temperature variation.
M. E. El Habbal (1995)
10.1016/S0003-4975(96)00743-6
Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass.
O. Moen (1997)
10.1016/0142-9612(96)85572-4
Leucocyte adhesion under flow conditions: principles important in tissue engineering.
D. Jones (1996)
10.1016/S0003-4975(96)00964-2
Heparin coating with aprotinin reduces blood activation during coronary artery operations.
C. Baufreton (1997)
Thrombin and human plasma kallikrein inhibition during simulated extracorporeal circulation block platelet and neutrophil activation.
Y. Wachtfogel (1998)
10.1172/JCI108710
Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes.
P. Craddock (1977)
Inhibition of the classical and alternative pathways by amino acids and their derivatives.
Y. Takada (1978)
10.1016/S0002-8703(98)70241-8
Blood flow and antithrombotic drug effects.
S. Hanson (1998)
10.1084/JEM.173.5.1281
Activation of the adhesive capacity of CR3 on neutrophils by endotoxin: dependence on lipopolysaccharide binding protein and CD14
S. Wright (1991)
10.1056/NEJM199106273242606
Oral anticoagulant drugs.
J. Hirsh (1991)
The pathways of blood coagulation
H. C. Hemker (1967)
10.1016/S0022-5223(96)70456-7
Effects of inhibition of complement activation using recombinant soluble complement receptor 1 on neutrophil CD11b/CD18 and L-selectin expression and release of interleukin-8 and elastase in simulated cardiopulmonary bypass.
A. Finn (1996)
10.1002/(SICI)1097-4636(199609)32:1<29::AID-JBM4>3.0.CO;2-R
Material-induced up-regulation of leukocyte CD11b during whole blood contact: material differences and a role for complement.
C. Gemmell (1996)
10.1163/156856293X00573
Identification of proteins absorbed to hemodialyser membranes from heparinized plasma.
R. Cornelius (1993)
10.1016/1054-8807(93)90056-8
Chapter 15 Device thrombosis and thromboembolism
S. Hanson (1993)
10.1016/S0022-5223(19)33735-3
Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion.
Y. Wachtfogel (1993)
10.1006/SCEL.1995.0034
Introduction: Cellular regulation of blood coagulation
C. Esmon (1995)
10.1016/S0022-5223(97)70373-8
Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: a clinical study.
M. Ernofsson (1997)
10.1016/S0049-3848(98)00157-1
Mechanical factors affecting hemostasis and thrombosis.
V. Turitto (1998)
The importance of platelets and complement in material-induced leukocyte activation in vitro
M. Gorbet (2001)
10.1055/S-0038-1648953
Neutrophil but not monocyte activation inhibits P-selectin-mediated platelet adhesion.
H. Rinder (1994)
10.1002/jlb.53.5.518
Interactions of lipopolysaccharide with neutrophils in blood via CD14
R. Weingarten (1993)
10.1002/(SICI)1097-4636(19990305)44:3<289::AID-JBM7>3.0.CO;2-O
Flow cytometric study of in vitro neutrophil activation by biomaterials.
M. Gorbet (1999)
10.1006/CLIN.1997.4413
Circulating endotoxin and cytokines after cardiopulmonary bypass: differential correlation with duration of bypass and systemic inflammatory response/multiple organ dysfunction syndromes.
K. Khabar (1997)
10.1016/0003-4975(93)90882-I
Heparin-coated bypass circuits reduce pulmonary injury.
J. Redmond (1993)
Pretreatment with a blocking monoclonal antibody to P-selectin accelerates pharmacological thrombolysis in a primate model of arterial thrombosis.
C. Toombs (1995)
10.1016/S1053-0770(97)80006-7
Cardiopulmonary bypass and the inflammatory response: a role for serine protease inhibitors?
J. Murkin (1997)
10.1055/S-0037-1615939
The relevance of blood cell-vessel wall adhesive interactions for vascular thrombotic disease.
A. May (1999)
10.1055/S-0038-1646352
Pentamidine: a non-peptide GPIIb/IIIa antagonist--in vitro studies on platelets from humans and other species.
D. Cox (1992)
10.1016/1054-8807(93)90045-4
Chapter 4 Mechanisms of inflammation and infection with implanted devices
J. Anderson (1993)
10.1111/J.1574-695X.1994.TB00442.X
Polymorphonuclear granulocyte expression of CD11a/CD18, CD11b/CD18 and L-selectin in normal individuals.
N. Rebuck (1994)
10.1002/JBM.820230404
Effect of heparin-PVA hydrogel on platelets in a chronic canine arterio-venous shunt.
C. H. Cholakis (1989)
10.1016/0006-2952(77)90185-X
Inhibition of the haemolytic complement activity by derivatives of benzamidine.
J. Hauptmann (1977)
10.1016/0026-2862(80)90054-0
The effect of shear rate on platelet interaction with subendothelium exposed to citrated human blood.
V. Turitto (1980)
10.1097/00002480-199407000-00071
Leukocyte adhesion molecules as biocompatibility markers for hemodialysis membranes.
K. von Appen (1994)
10.1055/S-2007-1010229
Response of the cellular immune system to cardiopulmonary bypass is independent of the applied pump type and of the use of heparin-coated surfaces.
M. Misoph (1998)
10.1093/NDT/12.3.492
Mechanisms of intra-dialyser granulocyte activation: a sequential dialyser elution study.
M. Grooteman (1997)
10.1159/000184109
Enhanced platelet aggregation and membrane biocompatibility: possible influence on thrombosis and embolism in hemodialysis patients.
P. Simon (1987)
10.1016/0735-1097(91)90951-5
Stenting of coronary arteries: has a modern Pandora's box been opened?
P. Serruys (1991)
10.1182/BLOOD.V79.5.1201.BLOODJOURNAL7951201
Cardiopulmonary bypass induces leukocyte-platelet adhesion.
C. Rinder (1992)
10.1016/0002-9343(85)90398-5
Hemodialysis-associated platelet activation and thrombocytopenia.
R. Hakim (1985)
Acute myocardial infarction and other acute ischemic syndromes
R. Califf (1996)
10.1055/S-0038-1648972
Alpha 1-antitrypsin Pittsburgh (Met358-->Arg) inhibits the contact pathway of intrinsic coagulation and alters the release of human neutrophil elastase during simulated extracorporeal circulation.
Y. Wachtfogel (1994)
10.1097/00001721-199304060-00017
Thrombogenic mechanisms in the human: fresh insights obtained by immunodiagnostic studies of coagulation markers.
M. Boisclair (1993)
10.1097/00005344-199600001-00004
Initiation of white cell activation during cardiopulmonary bypass: cytokines and receptors.
D. Cameron (1996)
Soluble complement receptor 1 inhibits both complement and granulocyte activation during ex vivo hemodialysis.
J. Himmelfarb (1995)
10.1016/0049-3848(95)00209-X
Cell biology of tissue factor, the principal initiator of blood coagulation.
E. Camerer (1996)
10.1016/S0022-5223(19)36757-1
Effects of simulated extracorporeal circulation on human leukocyte elastase release, superoxide generation, and procoagulant activity.
Russell F. Stahl (1991)
10.1016/S1010-7940(96)01062-7
Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes : a European multicentre study.
E. Fosse (1997)
10.1016/S0003-4975(98)00111-8
Monocyte tissue factor expression and ongoing complement generation in ventricular assist device patients.
C. Wilhelm (1998)
10.1177/039139889201500103
Granulocyte Elastase, β-Thromboglobulin, and C3D during Acetate or Bicarbonate Hemodialysis with Hemophan® Compared to a Cellulose Acetate Membrane
B. Stegmayr (1992)
10.1182/BLOOD.V72.6.2020.BLOODJOURNAL7262020
Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor
W. Novotny (1988)
10.1172/JCI119742
Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor.
C. Weber (1997)
10.1016/S1010-7940(99)00210-9
Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation.
H. Wendel (1999)
10.1016/S0162-3109(97)00057-X
Controlling the complement system in inflammation.
M. Kirschfink (1997)
10.1172/JCI113623
Up-regulation of the iC3b receptor (CR3) is neither necessary nor sufficient to promote neutrophil aggregation.
M. Philips (1988)
10.1177/0310057X9302100113
Complement (C3, C4) and C-reactive Protein Responses to Cardiopulmonary Bypass and Protamine Administration
M. Tulunay (1993)
10.1615/CRITREVIMMUNOL.V15.I2.10
Complement receptors in neutrophils.
H. Sengeløv (1995)
10.1182/BLOOD.V87.8.3271.BLOODJOURNAL8783271
Platelet-dependent primary hemostasis promotes selectin- and integrin-mediated neutrophil adhesion to damaged endothelium under flow conditions.
P. Kuijper (1996)
10.1016/S0140-6736(94)90509-6
Role of factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass
J. Burman (1994)
10.1016/S0735-1097(96)00308-7
Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplasty.
T. Inoue (1996)
10.1159/000045671
Hemodialysis-Induced Degranulation of Polymorphonuclear Cells: No Correlation between Membrane Markers and Degranulation Products
M. Grooteman (2000)
10.1016/S0022-5223(96)70395-1
Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass.
R. Gorman (1996)
10.1163/156856201753113114
Activation of platelets by in vitro whole blood contact with materials: Increases in microparticle, procoagulant activity, and soluble P-selectin blood levels
C. Gemmell (2001)
10.1016/S0002-9343(02)01145-2
Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization.
E. Topol (2002)
10.1378/CHEST.102.4_SUPPLEMENT.337S
Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.
J. Hirsh (1992)
10.1161/01.RES.72.5.1075
Tissue factor is expressed on monocytes during simulated extracorporeal circulation.
J. Kappelmayer (1993)
10.1016/0003-4975(93)90342-F
Neutrophil adhesion molecule expression during cardiopulmonary bypass with bubble and membrane oxygenators.
A. Gillinov (1993)
10.1177/039139889601900304
Modulation of CD11b/CD18 on Monocytes and Granulocytes following Hemodialysis Membrane Interaction in vitro
P. Thylén (1996)
10.1182/BLOOD.V76.6.1233.BLOODJOURNAL7661233
Activation mechanisms of adherent human neutrophils
I. Ginis (1990)
10.1016/S0022-5223(19)34384-3
Endotoxemia and enhanced generation of oxygen radicals by neutrophils from patients undergoing cardiopulmonary bypass.
A. Kharazmi (1989)
10.1172/JCI118195
Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.
C. Rinder (1995)
10.1016/0735-1097(96)00164-7
Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease?
J. K. Mickelson (1996)
10.1002/JBM.820291018
Contact activation during incubation of five different polyurethanes or glass in plasma.
K. W. van der Kamp (1995)
10.1053/SIIC.1999.0089
Stents and IIb/IIIa receptor blockers combined: usefulness in various types of coronary artery disease.
L. R. Wieken (1999)
10.1016/0140-6736(90)90815-M
Shear-induced platelet aggregation
J. O'brien (1990)
10.1046/j.1365-2141.1998.00674.x
Direct activation of factor X by monocytes occurs during cardiopulmonary bypass
R. Parratt (1998)
10.1002/JBM.820210310
Vascular graft-associated complement activation and leukocyte adhesion in an artificial circulation.
K. Kottke-Marchant (1987)
10.1016/S0735-1097(98)00532-4
Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty.
J. K. Mickelson (1999)
10.1163/156856200744255
What really is blood compatibility?
Michael V.Sefton (2000)
10.1182/BLOOD.V78.7.1730.BLOODJOURNAL7871730
Dynamics of leukocyte-platelet adhesion in whole blood
H. Rinder (1991)
10.1182/BLOOD.V75.5.1037.BLOODJOURNAL7551037
Structure and function of the leukocyte adhesion molecules CD11/CD18
M. A. Arnaout (1990)
10.1016/0022-3468(92)90787-8
Elevated levels of endotoxin, oxygen-derived free radicals, and cytokines during extracorporeal membrane oxygenation.
M. Hirthler (1992)
10.1111/j.1365-2141.1977.tb08809.x
Stimulation of Monocyte Procoagulant Activity by Adherence to Different Surfaces
C. Ginkel (1977)
10.1002/(SICI)1097-4636(199609)32:1<99::AID-JBM12>3.0.CO;2-D
Complement-mediated leukocyte adhesion on poly(etherurethane ureas) under shear stress in vitro.
W. J. Kao (1996)
10.1055/S-0038-1648803
Clues for understanding the structure and function of a prototypic human integrin: the platelet glycoprotein IIb/IIIa complex.
J. Calvete (1994)
10.1182/BLOOD.V69.1.324.BLOODJOURNAL691324
Human neutrophil degranulation during extracorporeal circulation
Y. Wachtfogel (1987)
10.1016/1054-8807(93)90054-6
Chapter 13 Principles underlying the role of adsorbed plasma proteins in blood interactions with foreign materials
T. Horbett (1993)
10.1016/0006-2952(79)90248-X
Pyridoxal 5'-phosphate--a new physiological inhibitor of blood coagulation and platelet function.
K. Subbardo (1979)
10.1002/jlb.56.6.672
Neutrophils, host defense, and inflammation: a double‐edged sword
John A. Smith (1994)
10.1111/j.1365-3083.1993.tb02564.x
Modification of the Complement Binding Properties of Polystyrene: Effects of End‐Point Heparin Attachment
U. Nilsson (1993)
10.1016/0092-8674(88)90567-3
The molecular basis of blood coagulation
B. Furie (1988)
10.1161/01.CIR.100.25.2499
Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass.
J. Fitch (1999)
10.1002/(SICI)1097-4636(199605)31:1<63::AID-JBM8>3.0.CO;2-O
Determination of contact phase activation by the measurement of the activity of supernatant and membrane surface-adsorbed factor XII (FXII): its relevance as a useful parameter for the in vitro assessment of haemodialysis membranes.
B. M. Matata (1996)
10.1163/156856200744273
Flow cytometric evaluation of material-induced platelet and complement activation
C. Gemmell (2000)
10.1161/01.CIR.93.11.2014
Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass.
J. H. Chung (1996)
Complement Activation by Biomaterials
R. Hakim (1993)
10.1038/KI.1996.33
Effects of ultrapure and non-sterile dialysate on the inflammatory response during in vitro hemodialysis.
C. Tielemans (1996)
10.1016/S0022-2143(98)90171-8
Sparsely adherent platelets support capture and immobilization of flowing neutrophils.
P. Bahra (1998)
10.1002/JBM.820231210
Identification of plasma proteins adsorbed to hemodialyzers during clinical use.
S. R. Mulzer (1989)
Granulocyte activation during hemodialysis.
W. Hörl (1986)
10.1016/1054-8807(93)90044-3
Chapter 3 Mechanisms of thrombus formation and dissolution
R. Colman (1993)
In vivo evaluation of artificial surfaces with a nonhuman primate model of arterial thrombosis.
S. Hanson (1980)
10.1016/0026-2862(90)90031-L
The effects of shear rate on the enzymatic activity of the tissue factor-factor VIIa complex.
C. Gemmell (1990)
10.1002/JBM.820280313
Mechanisms of biomaterial-induced superoxide release by neutrophils.
S. Kaplan (1994)
10.1097/00002480-199907000-00003
The inflammatory and coagulative response to prolonged extracorporeal membrane oxygenation.
G. Peek (1999)
10.1016/S0022-5223(99)70183-2
Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation.
C. Rinder (1999)
10.1182/BLOOD.V79.7.1712.BLOODJOURNAL7971712
The effect of leukocyte elastase on tissue factor pathway inhibitor.
D. Higuchi (1992)
10.1002/(SICI)1097-4636(199601)30:1<101::AID-JBM13>3.0.CO;2-R
Fibrinogen binding and platelet retention: relationship with the thrombogenicity of catheters.
A. Bailly (1996)
10.1006/SCEL.1995.0036
Inflammatory cell participation in coagulation.
D. Altieri (1995)
10.1128/IAI.63.7.2473-2477.1995
Expression of adhesion molecules on human granulocytes after stimulation with Helicobacter pylori membrane proteins: comparison with membrane proteins from other bacteria.
G. Enders (1995)
10.1016/0741-5214(84)90015-6
Complement activation by synthetic vascular prostheses.
A. Shepard (1984)
Monitoring of factor XII activity and granulocyte elastase release during cardiopulmonary bypass.
L. Irvine (1991)
A comparison of the pyrogenicity of environmental endotoxins and lipopolysaccharides.
Pearson Fc (1985)
10.1002/JBM.820280309
Factor XII fragment and kallikrein generation in plasma during incubation with biomaterials
K. W. H. J. V. D. Kamp (1994)
Adsorption of Hageman factor (factor XII) and other human plasma proteins to biomedical polymers.
N. Ziats (1990)
10.1002/JBM.820271105
Immobilization of poly(ethylene glycol) onto a poly(vinyl alcohol) hydrogel: 2. Evaluation of thrombogenicity.
G. R. Llanos (1993)
10.1111/J.1525-1594.1989.TB01552.X
Proteins adsorbed on hemodialysis membranes modulate neutrophil activation.
T. Kuwahara (1989)
10.1016/S0142-9612(98)00210-5
A new in vitro model to study interaction between whole blood and biomaterials. Studies of platelet and coagulation activation and the effect of aspirin.
J. Hong (1999)
The role of the complement system in hemostasis.
B. Ma (1986)
10.1016/S0272-6386(12)80473-2
Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during dialysis.
J. Himmelfarb (1991)
10.1073/PNAS.91.21.10119
Complement C3 participation in monocyte adhesion to different surfaces.
A. K. McNally (1994)
10.1055/S-0037-1614997
Microvesicles bind soluble fibrinogen, adhere to immobilized fibrinogen and coaggregate with platelets.
P. Holme (1998)
Inhibition of guinea pig complement by aromaticamidine and guanidine compounds.
D. Bing (1970)
10.1006/SCEL.1995.0037
Induction of cellular procoagulant activity by the membrane attack complex of complement.
P. Sims (1995)
10.1161/01.STR.29.9.1770
Mechanisms of cerebrovascular events as assessed by procoagulant activity, cerebral microemboli, and platelet microparticles in patients with prosthetic heart valves.
T. Geiser (1998)
10.1007/BF01709662
Bidirectional modulation of platelet and polymorphonuclear leukocyte activities
A. Maschio (2005)
10.1016/S0142-9612(97)80002-6
Coagulation on biomaterials in flowing blood: some theoretical considerations.
D. Basmadjian (1997)
10.1016/S0022-5223(99)70301-6
Heparin-coated cardiopulmonary bypass equipment. I. Biocompatibility markers and development of complications in a high-risk population.
V. Videm (1999)
10.1016/0735-1097(91)90530-M
Stenting of coronary arteries.
J. Beranek (1991)
10.1016/0167-5273(96)02611-3
Heparin-coated bypass circuits in cardiopulmonary bypass: improved biocompatibility or not.
M. Levy (1996)
10.1016/S0049-3848(03)00249-4
The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review.
D. Gustafsson (2003)
10.1016/0167-5699(95)80066-2
The production of cytokines by polymorphonuclear neutrophils.
M. Cassatella (1995)
Complement activation during extracorporeal therapy: biochemistry, cell biology and clinical relevance.
J. Rj (1994)
10.1021/JM00210A006
Inhibition of four human serine proteases by substituted benzamidines.
J. Andrews (1978)
10.1016/S0272-6386(12)81058-4
Effects of aprotinin on complement and granulocyte activation during ex vivo hemodialysis.
J. Himmelfarb (1994)
10.1038/359848A0
Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets
T. Palabrica (1992)
10.1159/000217309
The anti-GPIIb-IIIa agents: fundamental and clinical aspects.
B. Coller (1996)
10.1055/S-0037-1614981
Initiation and propagation of blood coagulation at artificial surfaces studied in a capillary flow reactor.
R. Blezer (1998)
10.1016/0142-9612(92)90010-L
Immune response in biocompatibility.
A. Remes (1992)
10.1006/BCMD.1995.0025
Platelet microparticles bind, activate and aggregate neutrophils in vitro.
W. Jy (1995)
10.1345/aph.10319
New Recommendations from the 1999 American College of Cardiology/American Heart Association Acute Myocardial Infarction Guidelines
S. Spinler (2001)
10.1016/0003-4975(94)90995-4
Complement and neutrophil activation during cardiopulmonary bypass: a study in the complement-deficient dog.
A. Gillinov (1994)
10.1016/S0162-3109(97)00064-7
Inhibition of complement activation by soluble recombinant CR1 under conditions resembling those in a cardiopulmonary circuit: reduced up-regulation of CD11b and complete abrogation of binding of PMNs to the biomaterial surface.
R. Larsson (1997)
10.1016/S0022-2143(98)90081-6
Platelet adhesion onto artificial surfaces: inhibition by benzamidine, pentamidine, and pyridoxal-5-phosphate as demonstrated by flow cytometric quantification of platelet adhesion to microspheres.
C. Gemmell (1998)
10.1016/S0022-5223(19)37043-6
Endotoxemia associated with cardiopulmonary bypass.
D. Rocke (1987)
Catheter coatings, blood flow, and biocompatibility.
R. Eberhart (1991)
10.4065/76.9.890
Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab.
A. Côté (2001)
10.7326/0003-4819-108-3-504_7
Hemostasis and thrombosis: Basic principles and clinical practice
R. Colman (1987)
10.1016/0003-4975(93)91048-R
Inflammatory response to cardiopulmonary bypass.
J. Butler (1993)
Methods for the detection of endotoxins present during extracorporeal circulation.
H. D. Lemke (1994)
Safety issues in heparin and protamine administration for extracorporeal circulation.
D. Jobes (1998)
Inhibition of fibrin deposition on the subendothelium by a monoclonal antibody to polymorphonuclear leukocyte integrin CD11b. Studies in a flow system.
M. Hernández (1997)



This paper is referenced by
10.3390/COATINGS11010093
Evaluation of Antithrombogenic pHPC on CoCr Substrates for Biomedical Applications
C. Bannewitz (2021)
10.1186/s13018-021-02226-7
In vivo performance of Al2O3-Ti bone implants in the rat femur
Marjan Bahraminasab (2021)
10.1016/J.SEPPUR.2020.117814
Synthesis of ceramic membrane using inexpensive precursors and evaluation of its biocompatibility for hemofiltration application
Roshni Meghnani (2021)
10.1016/J.MSEC.2020.111503
Improved hemocompatibility and reduced bacterial adhesion on superhydrophobic titania nanoflower surfaces.
Zachary Montgomerie (2021)
10.1038/s41598-020-78929-4
Tannic acid-functionalized HEPA filter materials for influenza virus capture
S. Kim (2021)
10.1007/s00383-020-04800-2
Pediatric and neonatal extracorporeal life support: current state and continuing evolution
Brian P. Fallon (2021)
10.1016/j.bioactmat.2020.08.001
Synergistic effects of immunoregulation and osteoinduction of ds-block elements on titanium surface
L. Chen (2021)
10.1016/J.COMMATSCI.2021.110418
The evaluation of anchoring processes and chemical stability of zwitterionic molecules via local reactivity indexes
O. P. Gomes (2021)
10.1016/J.REACTFUNCTPOLYM.2021.104894
Antioxidant and antithrombotic study of novel chitosan-diallyl disulfide inclusion complexes nanoparticles for hemodialysis applications
Muhamad Zulhilmi Zailani (2021)
10.3390/membranes11040273
Ultra-High Packing Density Next Generation Microtube Array Membrane for Absorption Based Applications
C. Chew (2021)
10.1016/j.bioactmat.2021.01.025
Polydopamine/poly(sulfobetaine methacrylate) Co-deposition coatings triggered by CuSO4/H2O2 on implants for improved surface hemocompatibility and antibacterial activity
Zhongqiang Zhu (2021)
10.3390/ma14061357
The State of the Art and Prospects for Osteoimmunomodulatory Biomaterials
Andreea-Mariana Negrescu (2021)
10.1016/j.colsurfb.2021.111562
In vitro haemocompatibility assessment of acrylic acid deposited on solid, polyurethane substrate.
R. Major (2021)
10.1080/14779072.2020.1792777
Tissue engineered heart valves for transcatheter aortic valve implantation: current state, challenges, and future developments
Nikolaos Poulis (2020)
10.1038/s41598-020-62122-8
A New Nanocomposite Copolymer Based On Functionalised Graphene Oxide for Development of Heart Valves
E. A. Ovcharenko (2020)
10.1080/09205063.2019.1710370
Improved mechanical properties by modifying fibrin scaffold with PCL and its biocompatibility evaluation
L. Yang (2020)
10.1016/j.buildenv.2020.106970
Ambient concentration of airborne microbes and endotoxins in rural households of southern India
M. Akila (2020)
10.3390/s20113149
Monitoring with In Vivo Electrochemical Sensors: Navigating the Complexities of Blood and Tissue Reactivity
P. Vadgama (2020)
10.1021/acsomega.0c00281
In Vitro Investigation of Hemocompatibility of Hydrothermally Treated Titanium and Titanium Alloy Surfaces
V. K. Manivasagam (2020)
10.1039/c9tb00879a
Pre-mounted dry TAVI valve with improved endothelialization potential using REDV-loaded PEGMA hydrogel hybrid pericardium.
L. Yang (2020)
10.7488/ERA/83
Development of in vitro and in vivo models to underpin advances in human radiotherapy
Edmund Mark Gray (2020)
10.1055/s-0040-1721741
Biomedical Uses of Sulfobetaine-Based Zwitterionic Materials
Francesco Zaccarian (2020)
10.1016/j.apsusc.2020.146539
A facile heparin/carboxymethyl chitosan coating mediated by polydopamine on implants for hemocompatibility and antibacterial properties
Yingying Jin (2020)
10.1016/j.matchemphys.2020.122911
A critical review of recent advances in hemodialysis membranes hemocompatibility and guidelines for future development
A. Mollahosseini (2020)
10.1016/j.msec.2019.110417
Nanofiber membranes as biomimetic and mechanically stable surface coatings.
M. Brunelli (2020)
10.1007/978-3-030-45489-0
Composite Materials: Applications in Engineering, Biomedicine and Food Science
S. Siddiquee (2020)
10.1007/s00398-019-00348-z
Systemminimalisierung im Rahmen der extrakorporalen Zirkulation
A. Bauer (2020)
10.1680/jsuin.19.00029
Endothelial cell growth on polyurethane modified with acrylic acid and REDV peptide
A. Butruk-RaszejaBeata (2020)
10.1371/journal.pone.0241444
A minimally invasive catheterization of the external jugular vein in suckling piglets using ultrasound guidance
H. Furbeyre (2020)
10.3390/medicines7090049
Minimising Blood Stream Infection: Developing New Materials for Intravascular Catheters
Charnete Casimero (2020)
10.3390/polym12051131
The Grafting of Multifunctional Antithrombogenic Chemical Networks on Polyurethane Intravascular Catheters
Yael Roth (2020)
10.1002/admt.202000136
Miniaturization of Artificial Lungs toward Portability
Mohammadhossein Dabaghi (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar